Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Circulation Journal

Volumn 70, Issue 7, 2006, Pages 880-884

  Veselka, Josef ^a   Duchoňová, Radka ^a   Páleníčková, Jana ^a   Zemánek, David ^a   Šváb, Přemysl ^a   Hájek, Petr ^a   Malý, Martin ^a   Blaško, Petr ^a   Tesař, David ^a   Červinka, Pavel ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Department of Cardiology   (Czech Republic)

Author keywords

Cardiomyopathy; Ethanol ablation; Obstruction

Indexed keywords

CREATINE KINASE MB;

ADULT; AGED; ALCOHOL SEPTAL ABLATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MORPHOLOGY; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 33745576540     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.880     Document Type: Article

References (26)

1. Hozumi T, Ito T, Suwa M, Sakai Y, Kitaura Y. Effects of dual-chamber pacing on regional deformation in patients hypertrophic obstructive cardiomyopathy. Circ J 2006; 70: 63-68.
2. Honda T, Shono H, Koyama J, Tsuchiya T, Hayashi M, Hirayama T, et al. Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy. Circ J 2005; 69: 536-542.
3. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-1706.
4. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
5. Chang SM, Lakkis NM, Franklin J, Spencer WH III, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 824-827.
6. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004; 5: 347-355.
7. Faber L, Welge D, Ziemssen P, Seggewiss H, Fassbender D, Horstkotte D. Septal ablation for hypertrophic obstructive cardiomyopathy: An analysis of the patients with dissatisfactory reduction of the outflow gradient. J Am Coll Cardiol 2002; 39(Suppl B): 22B.
8. Faber L, Welge D, Ziemssen P, Seggewiss H, Fassbender D, Horstkotte D. Septal ablation for hypertrophic obstructive cardiomyopathy: An analysis of the patients with dissatisfactory intervention results. J Am Coll Cardiol 2003; 41(Suppl A): 145A.
9. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Muller C, Kuhn H. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: Feasibility, clinical benefit, and short term results in elderly patients. Heart 2004; 90: 638-644.
10. Guo H, Wang J, Chen J, Shan J, Lee J-D, Ueda T. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients. Can J Cardiol 2004; 20: 779-782.
11. Lakkis NM, Franklin J, Spencer WH III, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 824-827.
12. Lakkis N, Nagueh S, Killip D, Torre G, Roberts R, Spencer W III. Nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor experience. J Interv Cardiol 2000; 13: 157-159.
13. Nagueh SF, Lakkis NM, He ZX, Middleton KJ, Killip D, Zoghbi WA, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998; 32: 225-229.
14. Nielsen C, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Short-term results in 50 consecutive procedures. Clin Cardiol 2003; 26: 275-279.
15. Seggewiss H, Faber L, Gleichmann U, Horstkotte D. Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2000; 35(Suppl A): 188A.
16. Veselka J, Duchoňová R, Procházková Š, Homolová I, Páleníčková J, Zemánek D, et al. The biphasic course of changes of left ventricular outflow gradientafter alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004; 60: 133-135.
17. Veselka J, Honěk T. Early remodeling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 2003; 88: 27-32.
18. Veselka J, Procházková Š, Duchoňová R, Bolomová-Homolová I, Páleníčková J, Zemánek D, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv 2004; 64: 231-235.
19. Veselka J, Duchoňová R, Procházková Š, Páleníčková J, Sorajja P, Tesař D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005; 95: 675-678.
20. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic cardiomyopathy. Eur Heart J 2003; 24: 1965-1991.
21. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, et al. Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003; 24: 320-328.
22. Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. Am J Cardiol 2003; 91: 1195-1198.
23. Thaman R, Gimeno JR, Reith S, Esteban MT, Limongelli G, Murphy RT, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol 2004; 44: 398-405.
24. Dalldorf FG, Willis PW IV. Angled aorta ("sigmoid septum") as a cause of hypertrophic subaortic stenosis. Hum Pathol 1985; 16: 457-462.
25. Dimitrow PP, Dubiel JS. Echocardiographic risk factors predisposing to sudden cardiac death in hypertrophic cardiomyopathy. Heart 2005; 91: 93-94.
26. Spirito P, Bellone P, Harris KM. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.